Galectin Therapeutics (GALT) grants CEO 84K options, 120K RSUs

Rhea-AI Filing Summary

Galectin Therapeutics Inc. reported new equity awards for its President and CEO, Lewis Joel, who also serves as a director. On January 16, 2026, he was granted 84,000 stock options with an exercise price of $3.04 per share under the company’s 2019 Omnibus Equity Incentive Plan. The options vest in four equal installments of 25% on June 30, 2026, December 31, 2026, June 30, 2027, and December 31, 2027.

On the same date, Joel also received 120,000 Restricted Stock Units (RSUs), which vest 100% on the earlier of December 31, 2026 or the signing of a partnership agreement. Each vested RSU converts into one share of Galectin common stock.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

LEWIS JOEL

(Last) (First) (Middle)

C/O GALECTIN THERAPEUTICS INC.

4960 PEACHTREE INDUSTRIAL BLVD., STE 240

(Street)

NORCROSS GA 30071

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
GALECTIN THERAPEUTICS INC [ GALT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

3. Date of Earliest Transaction (Month/Day/Year)
01/16/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock option (right to buy)(1)	$3.04	01/16/2026		A		84,000		(2)	01/16/2036	Common Stock	84,000	$0	65,000	D
Restricted Stock Unit(1)	(4)	01/16/2026		A		120,000		(3)	(3)	Common Stock	120,000	$0	100,000	D

Explanation of Responses:

1. Issued pursuant to the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan.

2. The options vest as follows: 25% on each of June 30, 2026? December 31, 2026? June 30, 2027? and December 31, 2027.

3. Restricted Stock Units vest 100% on the earlier of December 31, 2026 or signing of a partnership agreement.

4. The Restricted Stock Units, if vested, convert into Common Stock on a one for one basis.

	Jack W. Callicutt	01/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What equity awards did the Galectin Therapeutics (GALT) CEO receive?

The President and CEO, Lewis Joel, received 84,000 stock options with a $3.04 exercise price and 120,000 Restricted Stock Units on January 16, 2026.

How do the new stock options for the Galectin CEO vest?

The 84,000 stock options vest in four equal 25% installments on June 30, 2026, December 31, 2026, June 30, 2027, and December 31, 2027.

What is the vesting condition for the 120,000 RSUs reported by GALT?

The 120,000 RSUs vest 100% on the earlier of December 31, 2026 or the signing of a partnership agreement.

How do the Galectin RSUs convert into common stock?

Once vested, each Restricted Stock Unit converts into one share of Galectin common stock on a one-for-one basis.

Is the Galectin CEO a director as well as an officer in this filing?

Yes. The reporting person, Lewis Joel, is identified as both a director and an officer with the title President and CEO.

Were these Galectin equity awards part of a company incentive plan?

Yes. The filing states that the awards were issued pursuant to the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan.